Loading...
OTCM
RNLXY
Market cap32mUSD
Jun 10, Last price  
0.21USD
1D
1.43%
1Q
4.36%
IPO
33.13%
Name

Renalytix PLC

Chart & Performance

D1W1MN
P/E
P/S
30.82
EPS
Div Yield, %
Shrs. gr., 5y
23.71%
Rev. gr., 5y
-86.05%
Revenues
2m
-32.74%
0001,491,0002,970,0003,403,0002,289,000
Net income
-33m
L-26.64%
-1,254,000-5,559,000-9,250,000-31,010,000-56,732,000-45,607,000-33,456,000
CFO
-30m
L-7.84%
-422,000-3,994,000-10,061,000-24,632,000-45,745,000-32,674,000-30,111,000
Earnings
Sep 29, 2025

Profile

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
IPO date
Nov 06, 2018
Employees
102
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑06
Income
Revenues
2,289
-32.74%
3,403
14.58%
2,970
99.20%
Cost of revenue
31,174
60,056
29,651
Unusual Expense (Income)
NOPBT
(28,885)
(56,653)
(26,681)
NOPBT Margin
Operating Taxes
4
2
7,104
Tax Rate
NOPAT
(28,889)
(56,655)
(33,785)
Net income
(33,456)
-26.64%
(45,607)
-19.61%
(56,732)
82.95%
Dividends
Dividend yield
Proceeds from repurchase of equity
13,626
20,557
9,213
BB yield
-114.51%
-22.23%
-11.88%
Debt
Debt current
4,204
4,593
4,823
Long-term debt
4,376
7,728
8,249
Deferred revenue
Other long-term liabilities
Net debt
3,900
(15,281)
(28,270)
Cash flow
Cash from operating activities
(30,111)
(32,674)
(45,745)
CAPEX
(4)
(694)
Cash from investing activities
(4)
(694)
Cash from financing activities
10,250
15,118
25,515
FCF
(26,711)
(54,785)
(34,417)
Balance
Cash
4,680
26,142
44,077
Long term investments
1,460
(2,735)
Excess cash
4,566
27,432
41,194
Stockholders' equity
(212,747)
(100,335)
(52,720)
Invested Capital
213,428
130,919
108,457
ROIC
ROCE
EV
Common stock shares outstanding
108,179
82,210
73,837
Price
0.11
-90.22%
1.13
7.14%
1.05
-90.28%
Market cap
11,900
-87.13%
92,486
19.29%
77,529
-89.96%
EV
15,800
77,205
49,259
EBITDA
(28,521)
(54,161)
(24,068)
EV/EBITDA
Interest
2
Interest/NOPBT